At its monthly meeting, EMA's
https://nitter.cz/search?q=%23safety
committee, the
https://nitter.cz/search?q=%23PRAC
, concluded that the available evidence does not support linking GLP-1 receptor agonists with thyroid cancer.
🔎💊 More information in our meeting highlights:
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023
https://nitter.cz/search?q=%23SafetyOfMedicines
https://nitter.cz/search?q=%23PRAC

🐦🔗: https://nitter.cz/EMA_News/status/1717880381003673969#m

[2023-10-27 12:26 UTC]